Welcome to our dedicated page for Synbio Intl news (Ticker: SYIN), a resource for investors and traders seeking the latest updates and insights on Synbio Intl stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Synbio Intl's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Synbio Intl's position in the market.
Synbio International (OTC: SYIN) executed a Share Purchase Agreement and Warrant Agreement with FacialDx on Oct 8, 2025, acquiring 100,000 Class A shares and committing US$200,000 across four tranches over 12 months. Synbio also retains the right to convert up to US$2.5M of future clinical trial expenditures into FacialDx equity at today’s valuation. FacialDx received a warrant to buy 30,000,000 Synbio shares at $0.001 per share exercisable upon FDA approval. A Joint Trial Oversight Committee will govern clinical design and reporting to support FDA submission and commercialization.
Synbio International (OTC: SYIN) has appointed Ms. Desiree Cain, CPA, MBA as Chief Financial Officer and Board Member, effective immediately. Ms. Cain brings over 25 years of experience in corporate finance, accounting, and strategic growth management.
As CFO, she will lead financial operations, including accounting, reporting, and compliance with SEC and OTC Markets requirements. Her role will focus on developing governance frameworks and risk management strategies to align with public company best practices.
Synbio International Inc. (SYIN) has secured rights to conduct clinical trials for an innovative AI-powered depression screening technology called NIMS (Non-invasive Mental Screening). The technology, developed by FacialDx Inc., analyzes facial features through mobile or desktop devices to detect depressive symptoms.
The clinical trials will begin with a retrospective feasibility study, followed by a larger prospective validation trial if successful. NIMS utilizes advanced AI and machine learning algorithms to provide instant, cost-effective screening results, built on over 40 years of research by Dr. Todd Frisch.
The commercial strategy includes:
- Integration into clinical settings for medical practitioners
- Corporate partnerships in aviation, law enforcement, and emergency services
- Potential direct-to-consumer applications
With the U.S. medical device market projected to reach $6.45 billion by 2029, NIMS aims to revolutionize mental health screening by providing objective, data-driven analysis to complement traditional diagnostic methods.
FAQ
What is the current stock price of Synbio Intl (SYIN)?
What is the market cap of Synbio Intl (SYIN)?
